Boege F
Medizinische Poliklinik, Universität Würzburg, Germany.
Eur J Clin Chem Clin Biochem. 1996 Nov;34(11):873-88.
DNA topoisomerases are enzymes which control DNA topology by cleaving and rejoining DNA strands and passing other DNA strands through the transient gaps. Consequently these enzymes play a crucial role in the regulation of the physiological function of the genome. Beyond their normal functions, topoisomerases are important cellular targets in the treatment of human cancers. Some of the most powerful anti-cancer drugs used clinically stabilize the catalytic topoisomerase-DNA intermediates and, thus, cause DNA disorders that will induce apoptosis in proliferating cells. This review summarizes current protocols for measuring the catalytic activity of topoisomerases and for monitoring the molecular effects of topoisomerase-directed antitumour drugs in living cells and in cell-free assays. Furthermore, preanalytical factors are discussed, such as enzyme stability, methods for extracting DNA topoisomerases from cells, and protocols for separating subtypes and isoforms of these enzymes.
DNA拓扑异构酶是一类通过切割和重新连接DNA链,并使其他DNA链穿过瞬时缺口来控制DNA拓扑结构的酶。因此,这些酶在基因组生理功能的调节中起着至关重要的作用。除了其正常功能外,拓扑异构酶是人类癌症治疗中的重要细胞靶点。临床上使用的一些最有效的抗癌药物可稳定催化性拓扑异构酶-DNA中间体,从而导致DNA紊乱,进而诱导增殖细胞凋亡。本综述总结了目前用于测量拓扑异构酶催化活性以及监测拓扑异构酶导向抗肿瘤药物在活细胞和无细胞试验中的分子效应的实验方案。此外,还讨论了分析前的因素,如酶的稳定性、从细胞中提取DNA拓扑异构酶方法以及分离这些酶的亚型和同工型的实验方案。